Search

Your search keyword '"Pfizer Inc. -- Reports"' showing total 4,841 results

Search Constraints

Start Over You searched for: Descriptor "Pfizer Inc. -- Reports" Remove constraint Descriptor: "Pfizer Inc. -- Reports"
4,841 results on '"Pfizer Inc. -- Reports"'

Search Results

1. Researchers at Pfizer Report New Data on Migraine (Population Pharmacokinetic Modeling of Zavegepant, a Calcitonin Gene-related Peptide Receptor Antagonist, In Healthy Adults and Patients With Migraine)

2. Pfizer Researchers Release New Study Findings on Gene Therapy (Implementing a robust platform analytical procedure for measuring adeno-associated virus vector genome titer)

3. Researchers' from Pfizer Inc. Report Details of New Studies and Findings in the Area of Monoclonal Antibodies (Comprehensive characterization of higher order structure changes in methionine oxidized monoclonal antibodies via NMR chemometric ...)

4. Pfizer Research and Development Researcher Highlights Recent Research in Business (Mechanistic and Therapeutic Implications of Protein and Lipid Sialylation in Human Diseases)

5. Reports from Pfizer Add New Data to Findings in Antituberculosis Agents (Building Confidence In Physiologically Based Pharmacokinetic Modeling of Cyp3a Induction Mediated By Rifampin: an Industry Perspective)

6. New Atopic Dermatitis Findings from University of Cincinnati Reported (Patient-reported Outcome Measures In Chronic Spontaneous Urticaria, Angioedema, and Atopic Dermatitis)

7. New Clinical Trial Research Findings from Baylor University College of Medicine Outlined (What Is In a Name: Defining Pediatric Refractory Itp)

8. Studies in the Area of Chronic Myeloid Leukemia Reported from Saga University (Targeting Oxidative Phosphorylation with a Novel Thiophene Carboxamide Increases the Efficacy of Imatinib against Leukemic Stem Cells in Chronic Myeloid Leukemia)

9. New Obesity, Fitness and Wellness Findings Reported from Pfizer (Process Development for the First Gmp Synthesis of Sgd-9501-tfa, Part 2: Synthesis of the Payload, Linker, and Drug Linker)

10. New Cancer Research Study Findings Have Been Reported by Investigators at Memorial Sloan-Kettering Cancer Center (A Next-generation Braf Inhibitor Overcomes Resistance To Braf Inhibition In Patients With braf-mutant Cancers Using ...)

11. What Makes Companies Do the Right Thing?

12. Recent Findings in Colon Cancer Described by a Researcher from Odette Cancer Centre (Cost-effectiveness analysis of bevacizumab biosimilars for metastatic colorectal cancer: A comparative study using real-world data)

13. Study Results from MedStar Georgetown University Hospital Provide New Insights into Prostate Cancer (Patient Preferences for Attributes of Androgen Deprivation Therapies In Prostate Cancer: a Discrete Choice Experiment With Latent Class Analysis)

15. Studies from Washington University Add New Findings in the Area of Artificial Intelligence (Artificial Intelligence for Cardiovascular Care-part 1: Advances)

16. Researchers at Pfizer Report New Data on Solid Cancer (Evaluation of the Effect of Modafinil On the Pharmacokinetics of Encorafenib and Binimetinib In Patients With Braf V600-mutant Advanced Solid Tumors)

17. New Study Findings from Children's Hospital of The King's Daughters Illuminate Research in Anaplastic Large Cell Lymphoma (Podcast on Emerging Treatment Options for Pediatric Patients with ALK-Positive Anaplastic Large Cell Lymphoma and ...)

18. National Cancer Center Hospital Researcher Provides New Study Findings on Cancer (Clinical landscape of precision oncology for rare cancers among diverse Asian populations: Insights from the MASTER KEY registry)

19. Findings from Pfizer Worldwide Research and Development Provide New Insights into Drug Delivery Systems (Topical Drug Delivery By Sepineo P600 Emulgel: Relationship Between Rheology, Physical Stability, and Formulation Performance)

20. Findings from Pfizer Provide New Insights into Drug Research (Simulating Healthy Participant Pharmacokinetics for Renal and Hepatic Impairment Studies: Retrospective Assessment of the Approach)

21. Few Receive Meds for Opioid Use Disorder After Nonfatal Overdose

22. Investigators at Pfizer Report Findings in Immunoglobulins (Anti-drug Antibody Incidence Comparison of Therapeutic Proteins Administered Via Subcutaneous vs. Intravenous Route)

23. Research on Life Sciences Published by Researchers at Pfizer Inc. (Distinct fibroblast functions associated with fibrotic and immune-mediated inflammatory diseases and their implications for therapeutic development [version 1; peer review: 1 ...)

24. Atopic Dermatitis Negatively Impacts Mental Health

25. Studies from Brigham and Women's Hospital Provide New Data on Post-Operative Pain (Procedure-specific Postoperative Pain Management Guideline for Laparoscopic Colorectal Surgery a Systematic Review With Recommendations for Postoperative Pain ...)

26. Study Findings on Medicinal Chemistry Are Outlined in Reports from Pfizer Research and Development [Chemical Tools for the Gid4 Subunit of the Human E3 Ligase C-terminal To Lish (Ctlh) Degradation Complex]

27. Endometriosis Market expected to rise | Companies - AbbVie, Neurocrine Biosciences, ObsEva, Kissei Pharmaceuticals, SWK, Enteris BioPharma, Bayer, Hope Medicine, Tiumbio, Organon, expected to drive mar

28. FORM 8-K: PFIZER INC Files Current Report (Oct 29, 2024)

29. Heart Failure Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

30. FORM 8-K: PFIZER INC Files Current Report (Oct 15, 2024)

31. Metastatic Castration-Sensitive Prostate Cancer Clinical Trial Pipeline Insights Featuring 35+ Companies | DelveInsight

32. Metastatic Castration-Sensitive Prostate Cancer Clinical Trial Pipeline Insights Featuring 35+ Companies | DelveInsight

33. Metastatic Colorectal Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

34. Metastatic Castration-Resistant Prostate Cancer Clinical Trial Pipeline Appears Robust With 90+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

35. 2023 Pipeline Report

36. Nine in 10 top global companies failing to uphold human rights, report says

37. Reports Summarize Obesity, Fitness and Wellness Findings from Pfizer Research and Development (Early Process Development of Two Vanin-1 Inhibitors: Solid Form Challenges and Control of Ambident Reactivity)

38. Wakayama Medical University Researchers Provide New Insights into Kinase Inhibitors (Long-Term Efficacy and Safety of Lorlatinib in Japanese Patients With ALK-Positive Advanced NSCLC-A Brief Report From the CROWN Study)

39. New Findings from Pfizer Inc. in the Area of Apoptosis Reported (Comparative Analysis of Micronucleus Induction and Dna Damage Biomarkers In Tk6 and A375 Cells Using Flow Cytometry)

40. New Obesity, Fitness and Wellness Study Findings Have Been Reported by Investigators at University of Utah (Baseline Echocardiography and Laboratory Findings In Mis-c and Associations With Clinical Illness Severity)

41. Research from Pfizer Provides New Data on Pharmacy (The Impact of Formulation on Dissolution Coning: Supporting Development of a Classification System and Predictive Tool)

42. Pfizer Researchers Report Recent Findings in Pharmacy (Evaluation of Powder Flow Prediction by Ring Shear Testing at Low Consolidation Stresses)

43. Centre of Postgraduate Medical Education Researchers Detail New Studies and Findings in the Area of Pituitary Cancer (Pathologic Characteristics of Somatotroph Pituitary Tumors-An Observational Single-Center Study)

45. New Findings from Worldwide Research in the Area of COVID-19 Published (Dosing recommendation of nirmatrelvir/ritonavir using an integrated population pharmacokinetic analysis)

46. Research from Pfizer Inc. Provides New Study Findings on Respiratory Syncytial Viruses (A Statistical Model to Predict Protection Against Infant Respiratory Syncytial Virus Disease Through Maternal Immunization)

47. Data from Pfizer Broaden Understanding of Tetanus Vaccine (Antibody persistence and revaccination recommendations of MenACWY-TT: a review of clinical studies assessing antibody persistence up to 10 years after vaccination)

49. Studies from Pfizer Inc. in the Area of COVID-19 Published (Comprehensive Code List Associated with Underlying Medical Conditions Identified by the CDC as High-Risk Factors for Progression to Severe COVID-19 Outcomes)

50. Pfizer Inc. Files SEC Form 8-K, Current Report: (Oct. 29, 2024)

Catalog

Books, media, physical & digital resources